Hideki Terai
Overview
Explore the profile of Hideki Terai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
1012
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Initial single-institutional experience with salvage surgery for stage IV non-small-cell lung cancer
Hishida T, Oka N, Yano K, Omura S, Okubo Y, Masai K, et al.
Interdiscip Cardiovasc Thorac Surg
. 2025 Feb;
40(3).
PMID: 39951284
The purpose of this study was to assess surgical outcomes of salvage surgery for clinical stage IV non-small-cell lung cancer. A total of 14 patients who underwent lung resection following...
2.
Omasa H, Kakuta R, Terai H, Kawaida M, Hirai I, Tamura K, et al.
J Dermatol
. 2025 Feb;
PMID: 39932115
No abstract available.
3.
Shimada T, Maetani T, Chubachi S, Tanabe N, Asakura T, Namkoong H, et al.
J Cachexia Sarcopenia Muscle
. 2025 Jan;
16(1):e13721.
PMID: 39868664
Background: Chest computed tomography (CT) is a valuable tool for diagnosing and predicting the severity of coronavirus disease 2019 (COVID-19) and assessing extrapulmonary organs. Reduced muscle mass and visceral fat...
4.
Watase M, Shiraishi Y, Chubachi S, Tanabe N, Maetani T, Asakura T, et al.
Circ J
. 2025 Jan;
89(3):373-381.
PMID: 39828330
Background: Coronary artery calcification (CAC) detected through chest computed tomography (CT) strongly predicts cardiovascular events in asymptomatic individuals undergoing primary prevention. Few studies with limited sample sizes have investigated the...
5.
Okada M, Ohgino K, Horiuchi K, Sayama K, Arai D, Watase M, et al.
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768737
Atezolizumab, an immune checkpoint inhibitor (ICI), was used in a phase III clinical trial, i.e., the OAK trial, of previously treated patients with non-small cell lung cancer. We aimed to...
6.
Takaoka H, Kawada I, Hiruma G, Nagashima K, Terai H, Ishida N, et al.
BMJ Open Respir Res
. 2024 Dec;
11(1.
PMID: 39721744
Objectives: Severe acute respiratory syndrome coronavirus 2 significantly impacts Japan with a high number of infections and deaths reported. Long coronavirus disease (COVID) characterised by persistent symptoms after COVID-19 has...
7.
Konishi S, Masaki K, Shimamoto K, Ibuka Y, Goto R, Namkoong H, et al.
IJID Reg
. 2024 Dec;
14:100495.
PMID: 39717862
Objectives: We examined shifts in labor productivity and their economic ramifications among adult patients with long COVID in Japan. Methods: A total of 396 patients were categorized into three groups...
8.
Matsuyama E, Miyata J, Terai H, Miyazaki N, Iwasaki T, Nagashima K, et al.
Respir Investig
. 2024 Sep;
62(6):1094-1101.
PMID: 39342666
Background: Patients often experience multiple prolonged symptoms following acute coronavirus disease 2019 (COVID-19) recovery, defined as long coronavirus disease (COVID). Patients with long COVID may experience dyspnea during acute and...
9.
Shigematsu L, Kimura R, Terai H, Mimura Y, Ito D, Bun S, et al.
Ann Clin Transl Neurol
. 2024 Jul;
11(8):2188-2200.
PMID: 38961833
Objective: To reveal the clinical features and assess risk factors linked to brain fog and its societal implications, including labor productivity, providing valuable insights for the future care of individuals...
10.
Kamata H, Takamatsu K, Fukunaga K, Chubachi S, Nakagawara K, Namkoong H, et al.
Respir Investig
. 2024 Apr;
62(4):572-579.
PMID: 38669898
Background: No comprehensive analysis of the pulmonary sequelae of coronavirus disease 2019 (COVID-19) in Japan based on respiratory function tests and chest computed tomography (CT) has been reported. We evaluated...